| Today’s Big NewsOct 9, 2023 |
| By Angus Liu After years serving as a rumored target of Big Pharma M&A, Mirati Therapeutics has finally made its sale a reality. The buyer, Bristol Myers Squibb, will pay up to $5.8 billion for the KRAS drugmaker. |
|
|
|
By Annalee Armstrong,Max Bayer Eikon Therapeutics, a biotech that snatched several big-name executives from Merck & Co. and raked in some of the largest financing rounds in recent memory, has cut staff in an effort to “become more efficient.” |
By Andrea Park Revenues across the medtech industry clocked in at $573 billion for all of 2022, marking annual growth of just 3.5%—the industry’s lowest rate since 2015. |
By Gabrielle Masson You're not going to hear a private biotech trumpeting a down round as they announce a new batch of funding, but industry experts say the broader market trend has seeped into the sector. That's because a down round used to ring red-hot alarm bells. But as valuations change, investors say the meaning of a down round might too. |
|
Wednesday, October 18, 2023 | 11am ET / 8am PT Join industry experts for an exciting glimpse into the future of pharmaceutical innovation! Gain a comprehensive understanding of the latest strategies in organofluorine-based drug synthesis and learn key insights for staying ahead of the curve in this rapidly evolving landscape. Register now.
|
|
By Angus Liu Despite an endorsement from an advisory committee, the FDA has come to a different conclusion on the benefit-risk profile for Alnylam’s Onpattro in the rare heart disease transthyretin amyloidosis cardiomyopathy (ATTR-CM). |
By Conor Hale A look back at more than 18,400 patients with atrial fibrillation found that those who underwent a cardiac ablation procedure had less than half the risk of going on to develop heart failure. |
By Nick Paul Taylor AnaptysBio has set the stage for negotiations over its rare skin disease drug candidate, delivering phase 3 data that suggest the asset can challenge Boehringer Ingelheim in generalized pustular psoriasis (GPP). |
By Andrea Park This holiday season, the hottest electronic on sale at Best Buy just might be a continuous glucose monitor. |
By Zoey Becker Fujifilm Irvine Scientific laid off 57 staffers in California, while Florida's Formulated Solutions cut 66 of its workers. The layoffs were disclosed in recent Worker Adjustment and Retraining Notification (WARN) filings. |
By Fraiser Kansteiner Following similar initiatives to bolster mRNA vaccine production and access in Africa, the Bill & Melinda Gates Foundation is providing new funding to a clutch of drugmakers. |
By Conor Hale Delfi's first liquid biopsy test fulfills the company’s years-long prophecy to offer a new blood-based tool for the screening of lung cancer. |
Fierce podcastsDon’t miss an episode |
| In this episode of "The Top Line," we delve into the uncharted territory that pharma marketers face, from harnessing AI's potential to navigating the Inflation Reduction Act. |
|
|---|
|
|
|
Wednesday, November 1, 2023 | 1pm ET / 10am PT Join us to hear about a new, fully integrated and interoperable solution for Health at Home (Remote Care Delivery), with key insights on the journey from idea to market. You'll learn about EMR integration, managing data at scale, best practices on accelerating startup innovation, and much more. Register today!
|
|
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| WhitepaperCell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
| WebinarEmbark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
| eBookLearn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
| WhitepaperEconomic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
| WhitepaperFrom Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperLearn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| |
|
